BioElectronics Corporation (the manufacturer of ActiPatch®) has recently announced that its registry study of 44,000 users of its ActiPatch 7-day trial device has been published in the prominent peer reviewed medical journal Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35. More than 5,000 chronic pain sufferers responded to the survey and submitted an assessment.
Chronic pain is a major unmet medical need that affects 20 to 40% of the global population (more than diabetes, heart disease and cancer combined.) The majority of chronic pain causes, 80-85%, are musculoskeletal in nature. Despite using an average of 1.9 drugs for pain, 86% of the respondents reported that prior to using ActiPatch, they had pain levels of 8+ on a 11 point VAS scale- indicating severe unresolved pain. Pain was reduced an average of 57% for 65% of ActiPatch Therapy users who reported suffering from conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, sports injuries, post-surgical pain, tendonitis, and neuropathy. There were no side effects reported.
A 3-month follow-up survey indicated 80% of ActiPatch users continued to purchase and use ActiPatch. The long-term effectiveness of ActiPatch therapy was confirmed by 93% of survey respondents reporting sustained pain relief, a distinct decrease in their medication use, and a significant improvement in their quality of life.
Dr. Deepak Kotak, Executive VP of BioElectronics, a Fellow of the Royal College of Anesthesiologists said “Musculoskeletal pain is an increasing problem with few appropriate, safe, drug solutions. ActiPatch is a safe, affordable, self-treatment for chronic pain.” The details of previously completed and published clinical trials can be found at www.bielcorp.com/clinical-evidence.
Highlights of the 7-Day Trial Survey:
- 71% of the consumers had an average of 54% reduction in musculoskeletal, arthritic, post-surgery, fibromyalgia and neuropathy pain.
- 80% of the consumers said they “intended” to or would “maybe” purchase an ActiPatch after using the 7-day trial device
- Pain relief was maintained in 93% of long term users
- 67% of pain medication users, including opioid users, reported a moderate to complete elimination of pain medication use.
- 70% reported better sleep
- 74% reported they are more physically active
- 84% reported a moderate to a great deal better quality of life.
- There have been no adverse effects